Table 4 HIV, HBsAg, anti-HCV, HCV RNA detected and HCV viraemic rate among PWID (n = 943)
|  | Cape Town (n = 301) | Durban (n = 318) | Pretoria (n = 324) | Total (n = 943) | ||||
|---|---|---|---|---|---|---|---|---|
Male (n = 252) | Female (n = 49) | Male (n = 287) | Female (n = 31) | Male (n = 280) | Female (n = 44) | Male (n = 819) | Female (n = 124) | |
HIV +ve | 7% (16/244) | 9% (4/46) | 15% (42/286) | 39% (12/31) | 39% (107/277) | 36% (15/42) | 20% (165/807) | 26% (31/119) |
HBsAg + ve | 7% (17/249) | 0 (0/49) | 4% (12/287) | 3% (1/31) | 5% (14/278) | 7% (3/42) | 5% (43/814) | 3% (4/122) |
Anti-HCV + ve POC | 43% (108/ 250) | 47% (23/49) | 35% (101/287) | 35% (11/31) | 85% (237/278) | 79% (33/42) | 55% (446/815) | 55% (67/122) |
HCV RNA detected | 34% (86/250) | 27% (13/49) | 28% (81/287) | 26% (8/31) | 71% (196/278) | 48% (20/42) | 46% (363/815) | 34% (41/122) |
HCV viraemic rate | 80% (86/108) | 57% (13/23) | 80% (81/101) | 73% (8/11) | 83% (196/237) | 61% (20/33) | 81% (363/446) | 61% (41/67) |
HCV-HIV co-infection | 1% (3/244) | 2% (1/46) | 6% (18/286) | 13% (4/31) | 28% (77/277) | 24% (10/42) | 12% (98/807) | 13% (15/119) |
HCV-HBV co-infection | 3% (8/249) | 0 | 2% (5/287) | 0 | 2% (6/278) | 5% (2/42) | 2% (19/814) | 2% (2/122) |
HIV-HBV co-infection | 1% (2/243) | 2% (4/46) | 2% (4/286) | 3% (1/31) | 2% (5/277) | 5% (2/42) | 2% (11/806) | 3% (3/119) |